|
 
Technology Transfer Symposium:
Promoting Public-Private Collaboration for Innovation
Wednesday October 28, 2009
7 am – 12 pm PT
The Palace Hotel, San Francisco, CA
The Technology Transfer Symposium, held in conjunction with the BIO Investor Forum, will explore the domestic and international policy challenges for professionals in academia, industry, and legal areas regarding the administration of technology transfer. This groundbreaking meeting will bring together stakeholder groups to discuss the challenges and opportunities of today’s pressing policy issues impacting technology transfer and innovation policy, university – industry relationships, and unique collaborative and translational mechanisms. BIO will unveil a first-of-its-kind licensing survey as well as a study of the evolving benefits of the Bayh-Dole Act in today's economy.
What Can Attendees Expect?
Attendees will meet today's opinion leaders in intellectual property and technology transfer and biotechnology policy, examine and forecast domestic policy trends; study collaborations that successfully increased access to technology through unique partnerships both within the United States and internationally between governments, academia, philanthropic investors, companies and others; and exchange ideas on ways to foster sustainable, long-term biotechnology innovation.
Registration
The Symposium is free to attend, but space is very limited. For more information, email Margarita Noriega, Coordinator, Bioethics & IP, mnoriega@bio.org.
Understanding Technology Transfer
The U.S. leads the world in research and development of biotechnology products, due in large part to government support of basic research at universities. Government funding is awarded to top universities nationwide to sponsor research from the National Institutes of Health (NIH). Breakthroughs in basic research can lead to life-saving therapeutics through cooperative efforts of the public and private sectors. These efforts usually take the form of technology transfer agreements between NIH-funded institutions and biotechnology companies. In 1980, Congress approved The Bayh-Dole Act (see additional resources section).
In the past, discussions of "reasonable pricing" on NIH funded inventions upset the successful partnership between the private and public sector. Biotechnology companies need the freedom to license intellectual property in a manner that is beneficial to the public interest, and companies should not be hampered by price controls.
Additional Resources
- BIO Study Showing Industry/University Partnerships Critical to U.S. Economy (October 28, 2009)
Read the Press Release
Read the Study on Economic Benefits of Bayh-Dole Act
Read the Survey of Licensing Practices of BIO Member Companies
Read the Summary of Findings of Licensing Survey
- BIO Statement to the Secretary's Advisory Committee on Genetics Health & Society (October 8, 2009)
- GAO Report to Congress: Information on the Government’s Right to Assert Ownership Control over Federally Funded Inventions (July 2009)
- BIO Statement to the Secretary's Advisory Committee on Genetics, Health & Society (May 15, 2009)
- BIO Statement to the Senate Committee on the Judiciary on the Role of Federally-Funded University Research in the Patent System
(October 24, 2007) (438 KB PDF)
- BIO statement on the Bayh-Dole Act
(August 27, 2007) (78 KB PDF)
- Technology Transfer: Benefits from Biotech (July 10, 2007)
WGRI-2 Side-Event
- NIH: Moving Research From the Bench to the Bedside (July 10, 2003)
Testimony Before the Energy and Commerce Health Subcommittee of the U.S. House of Representatives
- Bayh-Dole and Technology Transfer (April 11, 2002)
Testimony Before the President's Council on Science and Technology
- Letter opposing use of Bayh-Dole march-in powers (May 24, 2004) (324 KB PDF)
- Statement Before the NIH Blue Ribbon Panel on Conflict of Interest Policies (April 16, 2004) (171 KB PDF)
- BIO letter to the editor of the Washington Post clarifying the Bayh-Dole Act (March 29, 2002) (66.3 KB PDF)
|
